Abstract:
The scheduling problem of a multi-cluster tool with a tree topology whose bottleneck tool is process-bound is investigated. A method for scheduling the multi-cluster tool to thereby generate an optimal one-wafer cyclic schedule for this multi-cluster tool is provided. A Petri net (PN) model is developed for the multi-cluster tool by explicitly modeling robot waiting times such that a schedule is determined by setting the robot waiting times. Based on the PN model, sufficient and necessary conditions under which a one-wafer cyclic schedule exists are derived and it is shown that an optimal one-wafer cyclic schedule can be always found. Then, efficient algorithms are given to find the optimal cycle time and its optimal schedule. Examples are used to demonstrate the scheduling method.
Abstract:
A computer system executes hierarchical MK splines for scattered data approximation. The computer system constructs an image by generating a final approximation function that approximates a scattered data set with a hierarchy of control lattice from coarsest to densest. The method includes executing MK splines approximation to the scattered data set with the hierarchy of control lattice to iteratively obtain approximation functions. The image is constructed by generating the final approximation function to construct an interpolated surface.
Abstract:
Prenylated isoflavones are suitable to specifically inhibit P-glycoprotein in multidrug-resistant cancer cells leading to an accumulation of cytotoxic compounds or therapeutic compounds in the cells while having exceptionally increased cytotoxic activity specifically towards multidrug-resistant cancer cells and while allowing for an increased activity of chemotherapeutic compounds towards which the cells are resistant.Also in accordance with the present invention is a method for specifically targeting cancer cells with multidrug-resistance as well as a method of potentiating the activity of a chemotherapeutic compound in multidrug-resistant cancer cells. In a further aspect, a kit including a prenylated isoflavone and a chemotherapeutic compound is provided.
Abstract:
A method for treating a subject suffering from a cancer, in particular a multidrug-resistant cancer includes administrating a cobalt-polypyridyl complex to the subject. A method for suppressing the growth of cancer cells, in particular inducing autophagy of the cancer cells, inducing cell cycle arrest of the cancer cells and/or inhibiting cell invasion of the cancer cells and for specifically targeting cancer cells with multidrug-resistance includes contacting said cancer cells with the cobalt-polypyridyl complex. A pharmaceutical composition and a kit are provided and include the cobalt-polypyridyl complex. Unexpectedly, the cobalt-polypyridyl complex is especially suitable to treat cancer, in particular multidrug-resistant cancer with an exceptionally increased cytotoxic activity towards multidrug-resistant cancer cells.
Abstract:
One embodiment relates to a method of treating lung cancer by administering a compound of formula I to a patient. Another embodiment relates to a method of treating cancer with a KRAS mutation that includes administering to a patient the compound with the following formula I:
Abstract:
One example embodiment relates to a method of treating lung cancer by administering a compound of formula I to a subject in need thereof. Another embodiment relates to a method to treat Non-Small Cell Lung Cancer (NSCLC) by administering the compound of formula I to a patient.
Abstract:
A method of isolating at least one phenanthroindolizidine alkaloid, in particular with HIF-1 inhibitory activity, from Tylophora atrofolliculata is used to isolate and obtain for example about 22 phenanthroindolizidine alkaloids, including at least 11 new phenanthroindolizidine alkaloids which have not been previously isolated. Experimental tests confirmed an exceptional HIF-1 inhibitory activity of the phenanthroindolizidine alkaloids isolated. A pharmaceutical composition includes at least one phenanthroindolizidine alkaloid and at least one pharmaceutical tolerable excipient. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid isolated from Tylophora atrofolliculata. A method of treating a subject suffering from cancer includes administering at least one phenanthroindolizidine alkaloid to the subject.
Abstract:
In widely deployed wireless “hot-spot” networks, nodes frequently join or leave, inelastic/elastic and saturated/non-satuarted flows coexist. In such dynamic and diverse environments, it is challenging to maximize the channel utilization while providing satisfactory user experiences. In this invention, one proposes a novel contention-on-demand (CoD) MAC scheme to address this problem. The CoD scheme consists of a fixed-CW algorithm, a dynamic-CW algorithm, and an admission control unit. The fixed-CW algorithm allows elastic flows to access limited system bandwidth; the dynamic-CW algorithm enables inelastic flows to contend for channel on demand and quickly adapt to network change; and the admission control unit rejects overloaded traffic for providing good user experiences. One then performs an asymptotic analysis to develop a simple but efficient admission control rule. Finally, extensive simulations verify that the scheme is very effective and the theoretical result is very accurate.
Abstract:
The present invention provides a compound that inhibits activity of oncogenic ROS1, a composition comprising said compound. The present invention also provides the use of said composition for treating cancer.
Abstract:
The present invention provides a method for updating a mobile terminal (MT) for a mobile communication network when the MT crosses a boundary of a first location-update (LA) area. The method comprises determining a second LA to be assigned to the MT for replacing the first LA. The second LA is characterized by a LA center and a LA size, both determined by optimizing them in a sense that a mean total location-management cost is minimized without restricting the LA center to be fixed at the initial position. The initial position is defined as the location where the MT performs a latest location update at the first LA before crossing the boundary. This invention also provides schemes of partitioning the second LA into sub-paging areas for use in paging the MT when a call arrives at the network, so as to minimize the paging cost while satisfying delay requirements.